Personalised medicine...always a good place to position a company.
Chemgenex might have made a better fist of commercialising Omapro if they had their companion diagnostic ready to go before the FDA asked for it. Would have helped their sale price too!
The plan is coming together, and @$6m mkt cap the buy signals are starting to ring a little louder!
